175 related articles for article (PubMed ID: 33859413)
1. Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD
Nat Chem Biol; 2021 Jul; 17(7):776-783. PubMed ID: 33859413
[TBL] [Abstract][Full Text] [Related]
2. Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1.
He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD
Biol Chem; 2018 Sep; 399(9):1091-1097. PubMed ID: 29447112
[TBL] [Abstract][Full Text] [Related]
3. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.
Khan T; Kryza T; Lyons NJ; He Y; Hooper JD
Cancer Res; 2021 May; 81(9):2259-2269. PubMed ID: 33509939
[TBL] [Abstract][Full Text] [Related]
4. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Casar B; He Y; Iconomou M; Hooper JD; Quigley JP; Deryugina EI
Oncogene; 2012 Aug; 31(35):3924-38. PubMed ID: 22179830
[TBL] [Abstract][Full Text] [Related]
5. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
6. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
7. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
8. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.
He Y; Wortmann A; Burke LJ; Reid JC; Adams MN; Abdul-Jabbar I; Quigley JP; Leduc R; Kirchhofer D; Hooper JD
J Biol Chem; 2010 Aug; 285(34):26162-73. PubMed ID: 20551327
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
11. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
[TBL] [Abstract][Full Text] [Related]
12. CUB domain-containing protein 1 (CDCP1) binds transforming growth factor beta family members and increase TGF-β1 signaling pathway.
Predes D; Cruz JVR; Abreu JG; Mendes FA
Exp Cell Res; 2019 Oct; 383(1):111499. PubMed ID: 31302030
[TBL] [Abstract][Full Text] [Related]
13. CDCP1 promotes compensatory renal growth by integrating Src and Met signaling.
Kajiwara K; Yamano S; Aoki K; Okuzaki D; Matsumoto K; Okada M
Life Sci Alliance; 2021 Apr; 4(4):. PubMed ID: 33574034
[TBL] [Abstract][Full Text] [Related]
14. Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development.
Ying X; Jiang X; Zhang H; Liu B; Huang Y; Zhu X; Qi D; Yuan G; Luo J; Ji W
Mol Cancer; 2020 Dec; 19(1):169. PubMed ID: 33267838
[TBL] [Abstract][Full Text] [Related]
15. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
16. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.
Wortmann A; He Y; Christensen ME; Linn M; Lumley JW; Pollock PM; Waterhouse NJ; Hooper JD
J Biol Chem; 2011 Dec; 286(49):42303-42315. PubMed ID: 21994943
[TBL] [Abstract][Full Text] [Related]
17. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Chopra S; Trepka K; Sakhamuri S; Carretero-González A; Zhu J; Egusa E; Zhou J; Leung K; Zhao N; Hooshdaran N; Feng FY; Wells JA; Chou J; Evans MJ
Clin Cancer Res; 2023 Apr; 29(7):1232-1242. PubMed ID: 36648492
[TBL] [Abstract][Full Text] [Related]
18. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A; D'Ambrosio M; Troiani M; Mosole S; Pellegrini L; Chen J; Revandkar A; Bolis M; Theurillat JP; Guccini I; Losa M; Calcinotto A; De Bernardis G; Pasquini E; D'Antuono R; Sharp A; Figueiredo I; Nava Rodrigues D; Welti J; Gil V; Yuan W; Vlajnic T; Bubendorf L; Chiorino G; Gnetti L; Torrano V; Carracedo A; Camplese L; Hirabayashi S; Canato E; Pasut G; Montopoli M; Rüschoff JH; Wild P; Moch H; De Bono J; Alimonti A
J Clin Invest; 2020 May; 130(5):2435-2450. PubMed ID: 32250342
[TBL] [Abstract][Full Text] [Related]
19. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
[TBL] [Abstract][Full Text] [Related]
20. CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.
He Y; Davies CM; Harrington BS; Hellmers L; Sheng Y; Broomfield A; McGann T; Bastick K; Zhong L; Wu A; Maresh G; McChesney S; Yau Wong K; Adams MN; Sullivan RC; Palmer JS; Burke LJ; Ewing AD; Zhang X; Margolin D; Li L; Lourie R; Matsika A; Srinivasan B; McGuckin MA; Lumley JW; Hooper JD
Oncogene; 2020 Jan; 39(1):219-233. PubMed ID: 31471585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
